We are on site at the Moscone Center in San Francisco, California at the 2020 Genitourinary Cancers Symposium!
We'll be recapping some of the top news presented each day during the meeting—and soon we’ll speak with Dr Laurence Albiges on the latest in renal cell carcinoma, as well as Dr Matthew Galsky on intriguing studies in bladder cancer.
Welcome to OncLive News Network! I'm Gina Columbus.
In bladder cancer, results of the phase II BLASST-1 trial showed that the neoadjuvant combination of nivolumab, gemcitabine, and cisplatin showed encouraging pathological downstaging rates in patients with muscle-invasive bladder cancer.
Results showed that the downstaging rate was 66%, and the pathologic complete response rate was 49%. Additionally, patients who had cT4N1 disease had a downstaging to pTa disease. Moreover, the regimen did not lead to added toxicity nor a delay in time to cystectomy.
Preliminary data from the phase II NEODURVARIB trial showed demonstrated that the combination of durvalumab and olaparib showed encouraging pathological complete response rates as a neoadjuvant treatment for patients with muscle-invasive bladder cancer.
Additionally, the regimen was found to be well tolerated in this patient population.
In locally advanced or metastatic urothelial carcinoma, the combination of enfortumab vedotin and pembrolizumab showed promising activity and durability as a frontline treatment for cisplatin-ineligible patients with metastatic urothelial carcinoma.
The data, which were from the multicohort EV-103 trial, showed that the combination had impressive response rates, including in those with liver metastases. The regimen also had a manageable safety profile.
Enfortumab vedotin is currently approved for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy.
The novel intravesical gene-mediated therapy nadofaragene demonstrated clinical activity in patients with Bacillus Calmette-Guerin-unresponsive, high-grade, nonmuscle-invasive bladder cancer, especially in those with carcinoma in situ, according to results of a multicenter, phase III trial.
Beyond being well tolerated, the regimen elicited responses early and remained durable for up to 1 year. Previously, the treatment showed activity in this patient population in a phase II trial.
That’s all for today. Stay tuned for tomorrow’s OncLive News Network: On Location, where we will sit down with Dr Daniel Petrylak on the latest in prostate cancer and bladder cancer, and Dr Brian Rini on some pivotal renal cell carcinoma trials.
Thank you for watching OncLive News Network! I'm Gina Columbus.